A unique collection of small molecule compounds for protein targets relevant for the CNS therapeutic area and neurological related diseases like Parkinson’s disease, Alzheimer’s disease, schizophrenia, drug dependence, etc.
It is patently obvious that CNS activity (and trans-cellular permeability in general) is a complex function of
physical/chemical properties of molecules such as size, lipophilicity, hydrogen-bonding potential, charge, and
conformation. For any given molecule, one of these factors may dominate others. Drugs with the brain as the site
of action should, in general, be able to cross the BBB. Drug delivery to the brain can be enhanced by increasing the
lipophilicity of the molecule, by using prodrugs that dissociate after crossing the BBB, or by using passive or active
drug targeting that utilizes transport systems at the BBB in the normal or disease states. In general, the transendothelial transport of compounds can depend on binding to constituents of the plasma, ionization state, timedependent plasma concentration, and cerebral flow. It is possible to modify many of these properties with changes in chemical structure.
Optimizing the distribution of therapeutic compounds between brain and blood is one of the key issues in
the design of novel CNS-active drugs.
Medicinal and Computational Chemistry Dept., ChemDiv, Inc.
12760 High Bluff Dr, San Diego, CA, 92130
Phone: + 1 916 234 0888
Fax: +1 858 794 4931
You can buy this library or customize your own library from our discovery collection of 1 600 000 compounds and 60 000 building blocks.